• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Impel NeuroPharma touts proof-of-concept trial for intranasal migraine drug

February 7, 2018 By Sarah Faulkner

Impel NeuroPharmaPrivately-held biotech Impel NeuroPharma touted positive results today from a Phase I trial of its acute migraine headache therapy.

The Seattle-based company’s drug is delivered intranasally using its Precision Olfactory Delivery device, which is designed to deliver drugs to the upper nasal cavity and target the brain using the olfactory and trigeminal nerves.

The proof-of-concept trial showed a statistically significant improvement in bioavailability compared to an approved nasal spray and that the bioavailability was comparable to an intravenous injection of the same drug, dihydroergotamine mesylate, after twenty minutes.

“DHE is a recognized gold standard treatment for acute migraine headache, however current delivery methods have created barriers to widespread use. This trial demonstrated that INP104 dosed via Impel’s POD device provided a consistent and desirable plasma pharmacokinetic profile,” Impel’s founder & chief scientific officer, John Hoekman, said in prepared remarks. “We are pleased with this outcome and we plan to commence a pivotal safety study in the United States in 2018.”

The trial also showed that most participants preferred Impel’s intranasal delivery method compared to traditional dosing regimens.

“In only a few months, Impel has generated compelling clinical data for INP104, and in 2018 we plan a rapid expansion in several clinical projects as we explore the use of the POD device in other CNS indications with unmet medical need,” CEO Jon Congleton added.

“The results of this trial support INP104 as a promising alternative for migraine patients and also validate the performance of the POD device to deliver medicine in a consistent and predictable manner via a novel intranasal route of administration.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals Tagged With: Impel NeuroPharma Inc.

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS